chemotherapy
Novacyt Secures IVDR Certification for Genetic Chemotoxicity Test
The assay is designed to identify cancer patients with an enzyme deficiency that can cause dangerous side effects from 5-fluorouracil treatment.
Lung Cancer Treatment Response, Outcomes Linked to Liquid Biopsy Profiles
An unresectable, locally advanced non-small cell lung cancer study highlighted molecular residual disease patterns associated with chemoradiation response and survival outcomes.
Cell-Free DNA Shows Promise as Cardiotoxicity Biomarker in HER2-Positive Breast Cancer Patients
The findings, published in JAMA Cardiology, show the role of cardiomyocyte-derived cell free DNA in predicting risk of post-chemotherapy cardiac problems.
FDA Updates Xeloda Labeling to Make DPYD Variant Risks More Explicit
In response to a citizen petition, the FDA has added more specific language about testing patients for DPYD gene variants that place them at risk for severe treatment-related toxicities.
Researchers reported prospective randomized trial data showing non-inferiority of adjuvant treatment guided by minimal residual disease testing.